WHO ICTRP trial
Effects of Tocilizumab (RoACTEMRA) on biomarkers in synovial tissue of patients…
NL-OMON36162 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON36162 |
|---|---|
| Public title | Effects of Tocilizumab (RoACTEMRA) on biomarkers in synovial tissue of patients with rheumatoid arthritis |
| Scientific title | Effects of Tocilizumab (RoACTEMRA) on biomarkers in synovial tissue of patients with rheumatoid arthritis - Mode of Action Tocilizumab |
| Primary sponsor | Academisch Medisch Centrum |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Observational invasive |
| Phase | 4 |
| Countries | Netherlands |
| Conditions | Rheumatiod Arthritis;10003816;Rheumatiod Arthritis |
| Interventions | ;Biomarkers;Rheumatoid Arthritis;RoACTEMRA;Tocilizumab |
| Registration date | Nov 20, 2012 |
| Target size | 20 |
| Secondary IDs | 2011-000768-86;NL35611.018.11 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: